Accuracy of ctDNA-based minimal residual disease detection in predicting postoperative recurrence of breast cancer: a meta-analysis

Key Points

• Postoperative recurrence predictions are improved with ctDNA-based minimal residual disease detection, which is crucial for breast cancer management.
• The analysis shows a significant predictive accuracy, with metrics indicating ctDNA can serve as a reliable biomarker.
• Meta-analysis conducted across multiple studies highlights ctDNA's effectiveness in monitoring postoperative outcomes in breast cancer.
• Implications underline the need for integrating ctDNA testing into clinical practice for enhanced patient monitoring post-surgery.